[go: up one dir, main page]

AU2001296558A1 - Inhibitors of angiogenesis and tumor growth for local and systemic administration - Google Patents

Inhibitors of angiogenesis and tumor growth for local and systemic administration

Info

Publication number
AU2001296558A1
AU2001296558A1 AU2001296558A AU9655801A AU2001296558A1 AU 2001296558 A1 AU2001296558 A1 AU 2001296558A1 AU 2001296558 A AU2001296558 A AU 2001296558A AU 9655801 A AU9655801 A AU 9655801A AU 2001296558 A1 AU2001296558 A1 AU 2001296558A1
Authority
AU
Australia
Prior art keywords
angiogenesis
inhibitors
local
tumor growth
systemic administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296558A
Inventor
Saira Sayed Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OncoPharmaceutical Inc
Original Assignee
OncoPharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoPharmaceutical Inc filed Critical OncoPharmaceutical Inc
Publication of AU2001296558A1 publication Critical patent/AU2001296558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001296558A 2000-10-03 2001-10-03 Inhibitors of angiogenesis and tumor growth for local and systemic administration Abandoned AU2001296558A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23742900P 2000-10-03 2000-10-03
US60237429 2000-10-03
PCT/US2001/030986 WO2002028387A1 (en) 2000-10-03 2001-10-03 Inhibitors of angiogenesis and tumor growth for local and systemic administration

Publications (1)

Publication Number Publication Date
AU2001296558A1 true AU2001296558A1 (en) 2002-04-15

Family

ID=22893665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296558A Abandoned AU2001296558A1 (en) 2000-10-03 2001-10-03 Inhibitors of angiogenesis and tumor growth for local and systemic administration

Country Status (3)

Country Link
US (1) US6696483B2 (en)
AU (1) AU2001296558A1 (en)
WO (1) WO2002028387A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3351246T3 (en) * 2001-02-19 2019-06-03 Novartis Pharma Ag Rapamycin derivatives for the treatment of a solid tumor associated with deregulated angiogenesis
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
UY27412A1 (en) * 2002-08-12 2003-06-30 Carlson Internat Inc A NEW PRODUCT FOR TICKET FIGHTING AND THE PREPAACINN PROCESS.
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
KR101288265B1 (en) 2003-09-03 2013-07-26 미스콘 트레이딩 에스.에이. Methods for the treatment of endometriosis
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
ATE451924T1 (en) 2004-03-15 2010-01-15 Sunesis Pharmaceuticals Inc SNS-595 AND METHODS OF USE
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US20050249685A1 (en) * 2004-04-27 2005-11-10 Natalia Botchkareva Reduction of hair growth
US20050288379A1 (en) * 2004-06-21 2005-12-29 Xiaoqiang Yan Benzoquinone compounds as anti-cancer agents
CN1875959B (en) * 2004-10-14 2010-05-12 孔庆忠 An anticancer pharmaceutical composition
US20080125858A1 (en) * 2004-12-08 2008-05-29 Elazer Edelman Materials and Methods For Treating and Managing Plaque Disease
WO2006069259A2 (en) * 2004-12-22 2006-06-29 The Gillette Company Reduction of hair growth
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
CA2605080A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
AU2006262682B2 (en) * 2005-06-21 2012-07-05 Shire Regenerative Medicine, Inc. Methods and compositions for enhancing vascular access
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
CA2641308A1 (en) * 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
EP2354138A1 (en) 2006-06-12 2011-08-10 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
EP2049109B1 (en) * 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
CN101583367B (en) * 2006-11-07 2013-05-01 夏尔再生医学公司 Materials and methods for treating and managing angiogenesis-mediated diseases
CN103788108B (en) 2007-02-06 2017-04-12 利克斯特生物技术公司 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
TWI407971B (en) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2009020565A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphates to treat neuroblastomas and medullogastomas
CN101854804B (en) * 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac inhibitors
AU2008317400B2 (en) * 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010014141A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US9351988B2 (en) 2011-05-02 2016-05-31 Universite De Geneve Macrocyclic lactones and use thereof
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
HK1218882A1 (en) * 2012-11-28 2017-03-17 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
US20140308236A1 (en) * 2013-01-08 2014-10-16 Technion Research And Development Foundation Ltd. Antimicrobial composition and uses thereof
KR20160004299A (en) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 Formulations of oxabicycloheptanes and oxabicycloheptenes
US11369588B2 (en) * 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
WO2016207913A1 (en) * 2015-06-23 2016-12-29 Jahangir Ali Fathima Benazir Plant based dye for staining of biological samples, extraction method and uses thereof
US11058700B2 (en) * 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
CN116585480A (en) 2016-12-08 2023-08-15 利克斯特生物技术公司 Oxabicycloheptanes for modulating immune responses
CN114886842A (en) * 2022-05-24 2022-08-12 吴丽莎 Preparation method and application of brefeldin A ointment
KR20240057723A (en) * 2022-10-25 2024-05-03 부산대학교 산학협력단 Pharmaceutical composition for preventing and treating fatty liver disease comprising ilimaquinone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059457A (en) 1976-02-19 1977-11-22 The University Of Delaware Chitin solution
US4062921A (en) 1976-02-19 1977-12-13 University Of Delaware Solvents for and purification of chitin
US4464389A (en) 1982-10-20 1984-08-07 Sri International Esters of retinoic acid and pentaerythritol and monobenzal acetals thereof
DE3247379A1 (en) 1982-12-22 1984-06-28 Basf Ag, 6700 Ludwigshafen BREFELDIN-A DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING UNWANTED PLANT GROWTH
US5428163A (en) 1986-12-31 1995-06-27 Mills; Randell L. Prodrugs for selective drug delivery
US4873092A (en) 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
DE3903797A1 (en) 1989-02-09 1990-08-16 Hoechst Ag METHOD FOR THE PRODUCTION OF ACTIVATED CHITOSANS AND THE USE THEREOF IN THE PRODUCTION OF CHITOSAN DERIVATIVES
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH04185601A (en) 1990-11-20 1992-07-02 Unitika Ltd Sustained release preparation containing platinum anticancer drug
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
GR920100122A (en) 1991-04-05 1993-03-16 Ethicon Inc Ionically crosslinked carboxyl-containing polysaccharides for adhension prevention.
ATE177629T1 (en) 1991-04-10 1999-04-15 Yu Ruey J USE OF COMPOSITIONS CONTAINING 2-HYDROXYCARBONIC ACID OR DERIVATIVES THEREOF FOR RELIEVING OCEAN NAIL CHANGES
WO1993025225A1 (en) 1992-06-17 1993-12-23 University Of Massachusetts Medical Center Liposomal formulations for administering to cancer patients
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5846952A (en) 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5696154A (en) 1994-06-29 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Brefeldin A derivatives and their utility in the treatment of cancer
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5786391A (en) 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
US5762903A (en) 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
EP0820305A2 (en) 1995-04-04 1998-01-28 Wound Healing of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5618837A (en) * 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
WO1997030705A1 (en) 1996-02-21 1997-08-28 Matrix Pharmaceutical, Inc. Use of cell membrane permeants in the treatment of cellular proliferative diseases
EA001779B1 (en) 1996-05-01 2001-08-27 Эли Лилли Энд Компани Thrapeutic treatment for vegf related diseases
US5932545A (en) 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
WO1999031084A1 (en) * 1997-12-18 1999-06-24 Purdue Research Foundation Brefeldin a derivatives
WO2000015766A1 (en) 1998-09-16 2000-03-23 Oncopharmaceutical, Inc. Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent

Also Published As

Publication number Publication date
US6696483B2 (en) 2004-02-24
US20020061303A1 (en) 2002-05-23
WO2002028387A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
AU2001296558A1 (en) Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2001256975A1 (en) Compositions and methods for inhibition of cancer invasion and angiogenesis
EP1097165A4 (en) Novel inhibitors of angiogenesis and tumor growth
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
AU2468401A (en) Underreamer and method of use
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2600800A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001273116A1 (en) Semiconductor device and method of formation
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU2001270778A1 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2596700A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU4825300A (en) Methods for inhibiting cutaneous inflammation and hyperpigmentation
AU2001275707A1 (en) Use of panaxatriol for stimulation angiogenesis
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU2001241771A1 (en) Use of avocado-soybean unsaponifiable preparations
AU2001251631A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
AU2002218084A1 (en) Inhibitors of thromboxane formation and action
HUP0301797A3 (en) Inhibition of angiogenesis and tumor growth
AU5571799A (en) Angiogenesis inhibitors and uses thereof
AU2001283486A1 (en) Methods of modulating wound healing and angiogenesis
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
IL144762A0 (en) Liposome composition and method for administration of radiosensitizer